Tumour-to-liver ratio determined by [ 68 Ga]Ga-DOTA-TOC PET/CT as a prognostic factor of lanreotide efficacy for patients with well-differentiated gastroenteropancreatic-neuroendocrine tumours

ConclusionsLow TLR, determined via [68Ga]Ga-DOTA-TOC PET/CT, can be a factor of worse prognosis in patients with advanced WD GEP-NETs treated with lanreotide.

Source: EJNMMI Research - June 14, 2020 Category: Radiology Source Type: research